Sugi Predict

Sugi Predict / Compounds / SCHEMBL885156

SCHEMBL885156

SCHEMBL885156

CC(=O)NCc1ccccc1C

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.66
▸ HPGD P15428 3/20 0.66
▸ KMT2A Q03164 3/20 0.60
▸ GAA P10253 2/20 0.60
▸ HTT P42858 1/20 0.60
▸ KDM4E B2RXH2 2/20 0.58
▸ SETDB1 Q15047 1/20 0.57
▸ LMNA P02545 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ CA2 P00918 1/20 0.53
▸ MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14204990 0.87 SETDB1 (0.59) ALDH1A1HPGDKMT2ASETDB1NPC1
SCHEMBL24576210 0.86 ALDH1A1 (0.68) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL2017132 0.86 ALDH1A1 (0.73) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL5670334 0.85 P2RX7 (0.52) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL1244426 0.82 ALDH1A1 (0.64) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL14651452 0.82 SETDB1 (0.54) ALDH1A1HPGDKMT2AHTTSETDB1
SCHEMBL13170238 0.81 ALDH1A1 (0.64) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL12757441 0.81 LMNA (0.63) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL5144070 0.81 ALDH1A1 (0.64) ALDH1A1HPGDKMT2AGAAHTT
SCHEMBL17787939 0.81 ALDH1A1 (0.62) ALDH1A1HPGDKMT2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115636798-A Preparation method and application of substituted triaminotriazine compound 中国人民解放军海军军医大学 2023-01-24 — — CN claimed
EP-2678342-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES Takeda Pharmaceutical Company Limited (JP) 2014-01-01 — — EP claimed
WO-2012148548-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-01 — — WO claimed
US-8148537-B2 Substituted acetophenones useful as PDE4 inhibitors LEO PHARMA A/S (DK) 2012-04-03 — — US claimed
EP-2125736-B1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA AS (DK) 2011-03-30 — — EP claimed
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA (DK) 2010-02-11 — — US claimed
CN-101611005-A Be used as the acetophenones of the replacement of PDE4 inhibitor LEO PHARMA AS (DK) 2009-12-23 — — CN claimed
EP-2125736-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS Leo Pharma A/S (DK) 2009-12-02 — — EP claimed
WO-2008077404-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA A/S (DK) 2008-07-03 — — WO claimed
CN-122036718-A ALK5 inhibitor and preparation method and application thereof 安炎达医药技术(广州)有限公司 2026-05-15 — — CN disclosed
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 Agomab Spain, S.L.U. (ES) 2025-10-30 — — US disclosed
CN-115636798-B Preparation method and application of substituted triamino triazine compound 中国人民解放军海军军医大学 2025-05-16 — — CN disclosed
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Agomab Spain, S.L.U. (ES) 2025-05-13 — — US disclosed
CN-117306080-A Composite fabric and preparation method and application thereof 波司登羽绒服装有限公司 2023-12-29 — — CN disclosed
EP-0545376-B1 Guanidino thiazoles and their use as H2-receptor antagonist FUJISAWA PHARMACEUTICAL CO (JP) 1998-09-09 — — EP disclosed
EP-0755949-A1 Radiation curable masses containing covalently bonded photoinitiators BASF AKTIENGESELLSCHAFT (DE) 1997-01-29 — — EP disclosed
US-5532258-A ANTIULCER AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-07-02 — — US disclosed
CN-1089259-A New compound FUJISAWA PHARMACEUTICAL CO (JP) 1994-07-13 — — CN disclosed
CN-1079469-A Preparation method with thiazole derivative of antiulcer activity and Histamine Receptors antagonistic action FUJISAWA PHARMACEUTICAL CO (JP) 1993-12-15 — — CN disclosed
EP-0545376-A1 Guanidino thiazoles and their use as H2-receptor antagonist FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-06-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297186-B2 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 TGFBR2, TGFBR1, ACVR1 ALDH1A1 1012/4885HPGD 2987/4885KMT2A 2848/4885
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS PDE4A, PDE4B, PDE3B ALDH1A1 457/4885HPGD 194/4885KMT2A 3607/4885
US-20250333395-A1 BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 TGFBR2, TGFBR1, ACVR1 ALDH1A1 1012/4885HPGD 2987/4885KMT2A 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.